Summary
The Prostate Cancer Prevention Trial (PCPT) Prostate Cancer Risk Calculator provides a single probability of prostate cancer and of high-grade disease (Gleason grade \(\geq\) 7) based on a man’s serum prostate-specific antigen (PSA) level, digital rectal examination (DRE) result, family history, age, race, and history of a prior prostate biopsy. Incorporating the panel of risk factors in addition to PSA, it is recommended for individually tailored biopsy discussions between doctors and patients. This chapter reviews the development of the PCPT Risk Calculator, the algorithm behind the calculator, ongoing validation studies, and proposed modifications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Thompson, I. M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lucia, M.S., Feng, Z., Parnes, H.L., Coltman, C.A., Jr. (2006) Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial Journal of the National Cancer Institute 98, 529–34.
Etzioni, R.D., Ankerst, D.P., Thompson, I.M. (2007) Is PSA velocity useful in early detection of prostate cancer? A critical appraisal of the evidence Journal of the National Cancer Institute 99, 489–90.
Parekh, D.J., Ankerst, D.P., Higgins, B.A., Hernandez, J., Canby-Hagino, E., Brand, T., Troyer, D., Leach, R., Thompson, I.M. (2006) External validation of the Prostate Cancer Prevention Trial risk calculator Urology 68, 1152–5.
Thompson, I.M., Ankerst, D.P., Chi, C., Goodman, P.J., Tangen, C.M., Lippman, S.M., Lucia, M.S., Parnes, H.L., Coltman, C.A., Jr. (2007) Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial Journal of Clinical Oncology 25, 3076–81.
Thompson, I.M., Chi, C., Ankerst, D.P., Goodman, P., Tangen, C., Lippman, S., Lucia, M.S., Parnes, H.L., Coltman, C.A. (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer Journal of the National Cancer Institute 98, 1128–33.
Marks, L.S., Fradet, Y., Deras, I.L., Blase, A., Mathis, J., Aubin, S.M.J., Cancio, A.T., Desaulniers, M., Ellis, W.J., Rittenhouse, H., Groskopf, J. (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69, 532–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ankerst, D.P., Thompson, I.M. (2009). Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator. In: Ankerst, D.P., Tangen, C.M., Thompson, I.M. (eds) Prostate Cancer Screening. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-60327-281-0_12
Download citation
DOI: https://doi.org/10.1007/978-1-60327-281-0_12
Publisher Name: Humana Press
Print ISBN: 978-1-60327-280-3
Online ISBN: 978-1-60327-281-0
eBook Packages: MedicineMedicine (R0)